GlassScriptPhysician profile
Paul Sarkaria
NPI 1902463300
$759.48
in general payments reported to CMS, 2019-2025
14 companies · $31.95 in 2025
The $31.95 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.91 · 2022: $379 · 2024: $257 · 2025: $31.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $125.00 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $121.86 | 2022 | |
| Amgen INC. | $113.46 | 2022 | |
| Abbvie INC. | $91.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.43 | 2024 | Ofev |
| Genzyme Corporation | $40.25 | 2024 | |
| Mylan Specialty L.P. | $39.30 | 2024 | Yupelri |
| United Therapeutics Corporation | $39.00 | 2024 | Tyvaso |
| Insmed, INC. | $31.95 | 2025 | Arikayce |
| 3b Medical, INC. | $29.03 | 2024 | Luna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.53 | 2024 | Glassia |
| Astrazeneca Pharmaceuticals LP | $18.31 | 2022 | |
| Intuitive Surgical, INC. | $17.17 | 2024 | |
| Erbe USA INC | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sarkaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.